rapid-acting insulin


Also found in: Dictionary, Thesaurus, Encyclopedia.

rapid-acting insulin

References in periodicals archive ?
Patients using premixed insulin without access to rapid-acting insulin have no way to correct hyperglycaemia, ensuring the failure of this insulin administration strategy and placing the child at high risk for diabetic ketoacidosis and complications of poor glycaemic control.
1c] levels are still [grearer than]7%, prandial rapid-acting insulin can be added, depending on blood glucose levels before lunch, supper and bedtime or the regimen can be changed to twice a day premix insulin to target postprandial hyperglycaemia.
If the basal insulin has a little or no peak, as with glargine or detemir or computerised infusion of rapid-acting insulin, little, if any, supplemental glucose is needed because insulin therapy more closely replicates physiological fasting (20).
Kaufman said Apidra is comparable to the two other approved rapid-acting insulins, insulin lispro and insulin aspart (NovoLog, Novo Nordisk).
European Commission approves new rapid-acting insulin analog for control of diabetes in children
Bolus insulin therapies, which include regular human insulin and the rapid-acting insulin analogs, are designed to control postprandial glycemia.
A new insulin immunoassay specific for the rapid-acting insulin analog, insulin aspart, suitable for bioavailability, bioequivalence, and pharmacokinetic studies.
This aerosol delivery system is about the size of a flashlight and uses rapid-acting insulin.
After a run-in period, during which all patients are optimized on their basal insulin regimen, at least 471 subjects are to be randomized to one of three arms for mealtime insulin: a control arm, in which patients utilize injected rapid-acting insulin, or one of two AFREZZA arms, one for the MedTone inhaler and the other for the next-generation inhaler.
For most adults, one unit of rapid-acting insulin can usually cover 15 grams of CHO.
Sulfonylureas can be used in combination with most other diabetes medications, but once patients begin shortor rapid-acting insulin, sulfonylureas are discontinued.
Results of the Market Acceptance Evaluation (MAE) study also demonstrated that physicians were more likely to recommend the innovative insulin delivery device to patients who are not at A1C goals or who are new to rapid-acting insulin (RAI) therapy.